IMA-203 is under clinical development by Immatics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase II drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMA-203’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMA-203 overview

IMA-203 is under development for the treatment of solid tumors include hepatocellular carcinoma ovarian cancer, endometrial cancer, uterine cancer, triple negative breast cancer, small-cell lung cancer, kidney carcinoma, cholangiocarcinoma, esophageal carcinoma, squamous non-small cell lung cancer, subtypes of synovial sarcoma, fibrosarcoma, rhabdomyosarcoma, thymic carcinoma, bladder cancer, uveal melanoma, cutaneous melanoma, head and neck squamous cell carcinoma. It is based on XPRESIDENT,  ACTengine platform and XCEPTOR platform. XPRESIDENT is a target discovery engine which identifies tumor-associated peptides (TUMAPs) / T-cell targets. ACTengine platform uses autologous T-cells which are genetically engineered to express T-cell receptors upon lentiviral transduction which recognize targets identified by XPRESIDENT. These cells are expanded ex-vivo and reinfused back into the patient. It acts by targeting cells expressing preferentially expressed antigen in melanoma (PRAME). It is administered through intravenous route.

Immatics overview

Immatics is a biopharmaceutical company focused on the development of T cell immunotherapies to fight against cancer. The company is headquartered in Tubingen, Baden-Wurttemberg, Germany.

For a complete picture of IMA-203’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.